Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.59)
# 252
Out of 5,042 analysts
136
Total ratings
49.58%
Success rate
41.68%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Initiates: Buy | $30 | $17.74 | +69.11% | 1 | Oct 10, 2025 | |
| HROW Harrow | Reiterates: Buy | $70 → $74 | $38.52 | +92.11% | 4 | Oct 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $460 → $560 | $421.50 | +32.86% | 13 | Sep 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $85 → $105 | $60.10 | +74.71% | 3 | Sep 23, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $74 → $80 | $57.83 | +38.34% | 4 | Sep 22, 2025 | |
| TGTX TG Therapeutics | Maintains: Buy | $53 → $55 | $33.34 | +64.99% | 14 | Sep 17, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $28 | $14.25 | +96.49% | 1 | Sep 12, 2025 | |
| ACTU Actuate Therapeutics | Initiates: Buy | $20 | $7.20 | +177.78% | 1 | Aug 26, 2025 | |
| ALT Altimmune | Maintains: Buy | $20 → $18 | $3.95 | +355.70% | 10 | Aug 13, 2025 | |
| MNOV MediciNova | Maintains: Buy | $6 → $5 | $1.23 | +308.16% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $3 | $1.84 | +63.04% | 2 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 → $2 | $0.36 | +454.02% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $10.51 | +90.29% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.70 | +76.47% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $15.96 | +119.30% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $38.00 | - | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $34.42 | +178.91% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.73 | -13.29% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $26 | $8.52 | +205.16% | 19 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $24.15 | +36.65% | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $16.31 | +758.37% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $3.80 | +2,268.42% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $4.14 | +3,764.73% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $1.98 | +152.53% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $3.78 | +1,064.02% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $2.51 | +3,485.66% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.90 | +268.42% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.49 | +301,913.42% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.88 | +143,517.02% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $11.22 | +586.27% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.38 | +104,247.83% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $5.23 | -23.52% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $94.65 | -58.80% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $4.29 | +693.47% | 1 | Mar 13, 2020 |
Zymeworks
Oct 10, 2025
Initiates: Buy
Price Target: $30
Current: $17.74
Upside: +69.11%
Harrow
Oct 1, 2025
Reiterates: Buy
Price Target: $70 → $74
Current: $38.52
Upside: +92.11%
Madrigal Pharmaceuticals
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $421.50
Upside: +32.86%
Nektar Therapeutics
Sep 23, 2025
Maintains: Buy
Price Target: $85 → $105
Current: $60.10
Upside: +74.71%
Cytokinetics
Sep 22, 2025
Maintains: Buy
Price Target: $74 → $80
Current: $57.83
Upside: +38.34%
TG Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $33.34
Upside: +64.99%
Theravance Biopharma
Sep 12, 2025
Initiates: Buy
Price Target: $28
Current: $14.25
Upside: +96.49%
Actuate Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $7.20
Upside: +177.78%
Altimmune
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $3.95
Upside: +355.70%
MediciNova
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.23
Upside: +308.16%
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.84
Upside: +63.04%
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.36
Upside: +454.02%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $10.51
Upside: +90.29%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.70
Upside: +76.47%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $15.96
Upside: +119.30%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $38.00
Upside: -
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $34.42
Upside: +178.91%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.73
Upside: -13.29%
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $8.52
Upside: +205.16%
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $24.15
Upside: +36.65%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $16.31
Upside: +758.37%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $3.80
Upside: +2,268.42%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $4.14
Upside: +3,764.73%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $1.98
Upside: +152.53%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $3.78
Upside: +1,064.02%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $2.51
Upside: +3,485.66%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.90
Upside: +268.42%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.49
Upside: +301,913.42%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.88
Upside: +143,517.02%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $11.22
Upside: +586.27%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.38
Upside: +104,247.83%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $5.23
Upside: -23.52%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $94.65
Upside: -58.80%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $4.29
Upside: +693.47%